Drug Profile
AERAS 422
Alternative Names: AERAS422Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aeras Global TB Vaccine Foundation
- Developer Aeras
- Class Antituberculars; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in USA (Intradermal, Injection)
- 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
- 02 Oct 2012 Aeras Global TB Vaccine Foundation is now called Aeras